Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
AbbVie Q4 Earnings Loom: Buy or Sell ABBV Stock Ahead of Results?

In This Article:

AbbVie ABBV is set to report fourth-quarter and full-year 2024 earnings on Jan. 31, before the opening bell. The Zacks Consensus Estimate for the quarter’s sales and earnings is pegged at $14.92 billion and $2.09 per share, respectively. The company’s earnings estimates for 2025 have declined from $12.27 per share to $12.17 in the past 30 days.

See the Zacks Earnings Calendar to stay ahead of market-making news.

Zacks Investment Research
Zacks Investment Research

Image Source: Zacks Investment Research

ABBV’s Earnings Surprise History

The pharma giant’s performance has been pretty impressive, with its earnings exceeding expectations in each of the trailing four quarters. It delivered a trailing four-quarter average earnings surprise of 2.29%. In the last reported quarter, AbbVie reported an earnings surprise of 2.74%.

Zacks Investment Research
Zacks Investment Research

Image Source: Zacks Investment Research

What Our Model Predicts for ABBV

Per our proven model, companies with the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), #2 (Buy) or #3 (Hold) have a goodchance of delivering an earnings beat. This is not the case here. You can uncover the best stocksto buy or sell before they’re reported with our Earnings ESP Filter.

AbbVie has an Earnings ESP of 0.00% and a Zacks Rank #3 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

Factors Shaping ABBV’s Upcoming Results

AbbVie’s top line in the fourth quarter is likely to have been driven by sales of newer immunology drugs, Skyrizi and Rinvoq. Approvals in new indications must have been driving strong revenues for both these drugs. The Zacks Consensus Estimate for Skyrizi sales is pegged at $3.58 billion, while the same for Rinvoq is pinned at $1.72 billion. Our model estimates for Skyrizi and Rinvoq sales are pegged at $3.56 billion and $1.70 billion, respectively.

ABBV lost patent protection for its blockbuster immunology drug Humira in the United States in January 2023 and has been facing sales erosion ever since. The drug lost exclusivity in ex-U.S. territories in 2018. The Zacks Consensus Estimate for Humira sales is pegged at $1.94 billion, while our estimate for the same is pinned at $1.92 billion.

We expect J&J JNJ-partnered Imbruvica sales to have declined due to competition from novel oral therapies. The Zacks Consensus Estimate and our model estimates for the J&J-partnered drug’s sales are pegged at $806 million and $819 million, respectively.

Roche RHHBY-partnered Venclexta sales are likely to have risen as new patient starts might have improved. The Zacks Consensus Estimate and our model estimates for the Roche-partnered drug’s sales are pegged at $674 million each.


Waiting for permission
Allow microphone access to enable voice search

Try again.